Sequence diversity of hepatitis C virus 6a within the extended interferon sensitivity-determining region correlates with interferon-alpha/ribavirin treatment outcomes

Virus Research

Volumn 153, Issue 1, 2010, Pages 44-49

  Zhou, Daniel X M ^a,b   Chan, Paul K S ^b   Zhang, Tiejun ^a   Tully, Damien C ^c   Tam, John S ^b,d  

^a FUDAN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF NEBRASKA   (United States)

^d Wyeth Vaccines Research   (United States)

Author keywords

Extended interferon sensitivity determining region (eISDR); Hepatitis C virus; Interferon treatment; Outcomes

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; VIRUS GENE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL PROTEINS;

HEPATITIS C VIRUS; HEPATITIS C VIRUS SUBTYPE 6A;

EID: 77956229613     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2010.07.004     Document Type: Article

References (29)

1. Derbala M., Amer A., Bener A., Lopez A.C., Omar M., El Ghannam M. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J. Viral Hepat. 2005, 12(4):380-385.
2. Duverlie G., Khorsi H., Castelain S., Jaillon O., Izopet J., Lunel F., Eb F., Penin F., Wychowski C. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J. Gen. Virol. 1998, 79(Pt 6):1373-1381.
3. Eddy S.R. Where did the BLOSUM62 alignment score matrix come from?. Nat. Biotechnol. 2004, 22(8):1035-1036.
4. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Izumi N., Marumo F., Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 1995, 96(1):224-230.
5. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Ogura Y., Izumi N., Marumo F., Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 1996, 334(2):77-81.
6. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347(13):975-982.
7. Girard S., Shalhoub P., Lescure P., Sabile A., Misek D.E., Hanash S., Brechot C., Beretta L. An altered cellular response to interferon and up-regulation of interleukin-8 induced by the hepatitis C viral protein NS5A uncovered by microarray analysis. Virology 2002, 295(2):272-283.
8. Halfon P., Halimi G., Bourliere M., Ouzan D., Durant J., Khiri H., Mercier L., Gerolami V., Cartouzou G. Integrity of the NS5A (amino acid 2209 to 2248) region in hepatitis C virus 1b patients non-responsive to interferon therapy. Liver 2000, 20(5):381-386.
9. Herion D., Hoofnagle J.H. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same. Hepatology 1997, 25(3):769-771.
10. Hofgartner W.T., Polyak S.J., Sullivan D.G., Carithers R.L., Gretch D.R. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J. Med. Virol. 1997, 53(2):118-126.
11. Hu Y., Tang M., Jiang W., Wu Y., Yuan Z., Wen Y. Association between NS5A gene sequence and response to interferon therapy in chronic hepatitis C patients in Shanghai. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2002, 16(2):114-118.
12. Hui C.K., Yuen M.F., Sablon E., Chan A.O., Wong B.C., Lai C.L. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J. Infect. Dis. 2003, 187(7):1071-1074.
13. Kato N., Lan K.H., Ono-Nita S.K., Shiratori Y., Omata M. Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator. J. Virol. 1997, 71(11):8856-8859.
14. Korth M.J., Katze M.G. Evading the interferon response: hepatitis C virus and the interferon-induced protein kinase, PKR. Curr. Top. Microbiol. Immunol. 2000, 242:197-224.
15. Lauer G.M., Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345(1):41-52.
16. Legrand-Abravanel F., Nicot F., Boulestin A., Sandres-Saune K., Vinel J.P., Alric L., Izopet J. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J. Med. Virol. 2005, 77(1):66-69.
17. Leung N., Chu C., Tam J.S. Viral hepatitis C in Hong Kong. Intervirology 2006, 49(1-2):23-27.
18. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958-965.
19. Ohno O., Mizokami M., Wu R.R., Saleh M.G., Ohba K., Orito E., Mukaide M., Williams R., Lau J.Y. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J. Clin. Microbiol. 1997, 35(1):201-207.
20. Pawlotsky J.M., Germanidis G. The non-structural 5A protein of hepatitis C virus. J. Viral Hepat. 1999, 6(5):343-356.
21. Poynard T., Yuen M.F., Ratziu V., Lai C.L. Viral hepatitis C. Lancet 2003, 362(9401):2095-2100.
22. Reed K.E., Rice C.M. Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321. J. Biol. Chem. 1999, 274(39):28011-28018.
23. Schinkel J., Spaan W.J., Kroes A.C. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. Antivir. Ther. 2004, 9(2):275-286.
24. Suzuki R., Suzuki T., Ishii K., Matsuura Y., Miyamura T. Processing and functions of Hepatitis C virus proteins. Intervirology 1999, 42(2-3):145-152.
25. Tan S.L., Katze M.G. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 2001, 284(1):1-12.
26. Tanimoto A., Ide Y., Arima N., Sasaguri Y., Padmanabhan R. The amino terminal deletion mutants of hepatitis C virus nonstructural protein NS5A function as transcriptional activators in yeast. Biochem. Biophys. Res. Commun. 1997, 236(2):360-364.
27. Veillon P., Payan C., Gaudy C., Goudeau A., Lunel F. [Mutation analysis of ISDR and V3 domains of hepatitis C virus NS5A region before interferon therapy with or without ribavirin]. Pathol. Biol. (Paris) 2004, 52(9):505-510.
28. Yuen M.F., Lai C.L. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology 2006, 49(1-2):96-98.
29. Zeuzem S., Lee J.H., Roth W.K. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997, 25(3):740-744.